News & Videos - BIONXT SOLUTIONS INC XPHYF - English

DGAP-News: XPhyto Therapeutics Corp. / Key word(s): Miscellaneous Oettinger Brewery Signs Exclusive Agreement with Xphyto for Cannabis-Infused Beverages 13.05.2020 / 04:37 The issuer is solely responsible for the content of this announcement. VANCOUVER, BC / ACCESSWIRE / May 12, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY)(FSE:4XT)(OTC PINK:XPHYF) ("XPhyto" or the "Company") is pleased to announce that it has signed a standstill agreement and letter of intent (the "Agreement") for cooperation in...

VANCOUVER, BC / ACCESSWIRE / May 12, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY)(FSE:4XT)(OTC PINK:XPHYF) ("XPhyto" or the "Company") is pleased to announce that it has signed a standstill agreement and letter of intent (the "Agreement") for cooperation in the field of development, production, and distribution of new cannabis-infused beverages and products with the renowned German brewery OETTINGER Brauerei GmbH ("Oettinger"). XPhyto and Oettinger have agreed to pursue the signing of an...

VANCOUVER, BC / ACCESSWIRE / April 22, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTCPINK:XPHYF) ("XPhyto" or the "Company") is pleased to announce that further to its press release on April 20, 2020, regarding a definitive development, technology purchase and licence agreement (the "Agreement") with 3a-Diagnostics GmbH ("3a"), XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has taken delivery of certain pathogen-specific peptide biosensors from 3a for the...

VANCOUVER, BC / ACCESSWIRE / April 20, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC PINK:XPHYF) ("XPhyto" or the "Company") is pleased to announce that it has signed a definitive development, technology purchase and licence agreement (the "Agreement") with 3a-Diagnostics GmbH ("3a") for the development and commercialization of real-time, low-cost and easy-to-use oral dissolvable thin film ("ODF") screening tests for the rapid detection of infectious diseases. 3a is a research-based...

DGAP-News: XPhyto Therapeutics Corp. / Key word(s): Miscellaneous RETRANSMISSION: COVID-19 Test and Development Programs Update 23.03.2020 / 08:02 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - March 23, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC PINK: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19...

Vancouver, British Columbia--(Newsfile Corp. - March 23, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC PINK: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19 (SARS-CoV-2) pandemic. XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has entered into a binding standstill agreement with a European biotechnology company for development of a low-cost rapid real-time...

DGAP-News: XPhyto Therapeutics Corp. / Key word(s): Miscellaneous XPhyto Announces COVID-19 Test and Development Programs Update 20.03.2020 / 21:15 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - March 20, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19...

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19 (SARS-CoV-2) pandemic. XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has entered into a binding standstill agreement with a European biotechnology company for development of a low-cost rapid real-time...

DGAP-News: XPhyto Therapeutics Corp. / Key word(s): Miscellaneous XPhyto Therapeutics Epilepsy Treatment Program 19.03.2020 / 17:45 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - March 19, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC: XPHYF) ("XPhyto" or the "Company") is pleased to announce significant progress with respect to development of its cannabidiol ("CBD") based Epilepsy product. Further to the...

Vancouver, British Columbia--(Newsfile Corp. - March 19, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC: XPHYF) ("XPhyto" or the "Company") is pleased to announce significant progress with respect to development of its cannabidiol ("CBD") based Epilepsy product. Further to the Company's press release dated December 9, 2019, titled "Epilepsy Treatment to be Developed with XPhyto Therapeutics Thin Film Delivery System," and based on recent positive product development results,...

DGAP-News: XPhyto Therapeutics Corp. / Key word(s): Miscellaneous XPhyto Therapeutics Initiates Infectious Disease Programs 03.03.2020 / 09:05 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - March 3, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), will be commencing several research and...

Vancouver, British Columbia--(Newsfile Corp. - March 3, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), will be commencing several research and development programs related to infectious disease. These programs include in-vitro study of thin film delivery of cannabigerol (CBG) and quercetin for potential anti-bacterial and anti-viral treatments, respectively, as...

DGAP-News: XPhyto Therapeutics Corp. / Key word(s): Miscellaneous Exclusive Strategic Partnership Commenced Between XPhyto Therapeutics and Elite Bavarian Brewing & Beverage Institute Weihenstephan 18.02.2020 / 09:05 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - February 18, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary,...

Vancouver, British Columbia--(Newsfile Corp. - February 18, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH ("Bunker"), has begun its strategic exclusive partnership for research and development of cannabis focused products, specifically beverages, with the chair of brewing and beverage technology at the Technical University of Munich ("TUM"), School of Life Sciences...

DGAP-News: XPhyto Therapeutics Corp. / Key word(s): Miscellaneous XPhyto Therapeutics Announces Strategic Supply, Import and Distribution Agreement for the German Cannabis Market 27.01.2020 / 13:30 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that the Company has signed a three year definitive supply,...

Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that the Company has signed a three year definitive supply, import and distribution agreement (the "Agreement") with PharmaCielo Ltd. ("PharmaCielo"), one of the largest, highest quality, and lowest cost cannabis cultivators in the world. PharmaCielo ( TSXV: PCLO) (OTCQX: PCLOF ) is a global company, headquartered in Canada, with a...